Passage Bio Announces Positive Interim Clinical Data from :

Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna...

Related Keywords

Philadelphia , Pennsylvania , United States , University Of Pennsylvania , Stuart Henderson , Mark Forman , Mike Beyer , William Chou , University Of Pennsylvania Gene Therapy Program , European Commission , Drug Administration , Passage Bio Inc , Healthcare Communications , Nasdaq , Sam Brown Inc , Exchange Commission , Clinical Development , Passage Bio , Orphan Drug , Rare Pediatric Disease , Gene Therapy Program , Private Securities Litigation Reform Act , Risk Factors , Nasdaq Pasg ,